Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan
The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2
These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare
(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively.
This expansion follows Alastin’s recent launches in China and Australia and underscores Galderma’s continued investment in JPAC, a region characterized by advanced skincare practices and rapid growth in injectable aesthetics.1,2 This is increasing demand for integrated skincare solutions that support skin readiness, recovery and long-term quality.3,4,5
Alastin addresses this need through its range of peri-procedural support and daily skincare products that amplify the skin’s natural regenerative abilities, supporting recovery and enhances visible outcomes of in-demand aesthetic procedures such as energy-based device and injectable treatments.6-13 Select Alastin products are powered by proprietary TriHex Technology®, which uniquely combines peptide components that help clear aged, damaged collagen and elastin while simultaneously supporting the production of new, healthy collagen and elastin – a dual mechanism that underpins its regenerative approach.6,7,11,14 Restorative Skin Complex with TriHex+™ features the next evolution of this technology, which supports the skin’s natural production of high molecular weight hyaluronic acid (HA), while further enhancing collagen and elastin production, contributing to long-term skin longevity.15,16
With more than 60 international dermatological publications and over 25 granted patents, Alastin is one of the most clinically studied skincare brands.17,18 In the United States it is the number one peri-procedural option and continues to be one of the fastest-growing global medical aesthetics skincare brands.19 It is powered by a proprietary peptide-based synergistic combination of ingredients and supported by real-world clinical experience demonstrating high levels of patient satisfaction, including improvements in radiance, recovery following procedures, and sustained hydration as well as overall skin resilience.7-9,11,16,20,21
The Alastin Skincare portfolio uses deep regenerative science to push the boundaries of what skincare can do and address a broad spectrum of needs across the aesthetic journey.8,9 Nine products will be available in the JPAC region, including:
Procedure support products, Skin Nectar and INhance – both with TriHex Technology® – developed for peri-procedural use to enhance visible outcomes and reduce recovery time7,16,20,22-26
Daily treatment products:
Rejuvenate products, designed to support ongoing collagen and elastin renewal:27-29 Restorative Skin Complex with TriHex+™, Restorative Eye Complex with TriHex Technology®, and Restorative Neck Complex with TriHex Technology®
Targeted serums formulated to address specific skin concerns:30-33 C-RADICAL Defense (an antioxidant serum that protects against environmental stressors), A-LUMINATE Brightening Serum™ (reduces the appearance of hyperpigmentation and discoloration for a more even skin tone), and HA IMMERSE Serum™ (enhances skin hydration)
Daily care products to help moisturize, nourish and soothe skin:34,35 Ultra Nourishing Moisturizer with TriHex Technology®
JPAC is a key growth engine for Galderma. By introducing Alastin, Galderma is expanding access to a holistic regenerative skincare portfolio designed to address some of today’s most significant aesthetic trends and needs, from an increased focus on skin quality and longevity, to growing concerns around menopause-related skin health, medication-driven weight loss, and aging.
About Alastin
Alastin by Galderma is the leader in peri-procedural regenerative skincare, offering innovative, scientifically proven, and clinically tested products. The Alastin Skincare portfolio provides a comprehensive collection of cutting-edge formulas designed specifically for peri-procedural use, as well as daily skincare regimens, all powered by proprietary peptides and innovative, clinically meaningful, science-backed ingredients designed to amplify the skin’s own natural regenerative abilities. With more than 60 international dermatological publications and over 25 patents granted, Alastin is one of the most clinically studied professional-grade skincare brands.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260719444150/en/
Permalink
https://www.aetoswire.com/en/news/54572121
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
No comments:
Post a Comment